AR041260A1 - Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia - Google Patents
Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofreniaInfo
- Publication number
- AR041260A1 AR041260A1 ARP030103336A ARP030103336A AR041260A1 AR 041260 A1 AR041260 A1 AR 041260A1 AR P030103336 A ARP030103336 A AR P030103336A AR P030103336 A ARP030103336 A AR P030103336A AR 041260 A1 AR041260 A1 AR 041260A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- atoms
- ring
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque X es S, O, SO, SO2, CH2 o NR10, Y es N o CH; A es -(CH2)mCH2- o -(CH2)mO-, -(CH2)mNR11, o -(CH2)mC(R12R13)- en las que R12 y R13 se seleccionan independientemente entre alquilo C1-4opcionalmente sustituido con uno a tres átomos de F, alcoxi C1-4 opcionalmente sustituido con uno a tres átomos de F, hidroxi y aminoalquilo; o R12 y R13, junto con el átomo de C al cual están unidos forman un grupo carbonilo; m es un número enterode 1 a 4; R4 y R9 se seleccionan independientemente entre H, alquilo C1-4 opcionalmente sustituido con uno a tres átomos de F, alcoxi C1-4 opcionalmente sustituido por uno a tres átomos de F, halógeno, nitro, ciano, amino, alquil (C1-4)-amino ydialquil (C1-4)-amino; o, cuando X es NR10, uno de R4 y R9 puede formar, junto con el átomo de C al cual está unido, y junto con R10 y el N al cual está unido, un anillo heterocíclico que contiene de 4 a 7 miembros de anillo, de los cuales de 1 a 3miembros de anillo son heteroátomos seleccionados entre N, O, y S, y de los cuales los restantes miembros de anillo son C, con la condición de que cuando R11 forma un anillo con uno de R4 y R9, el otro de R4 y R9 está ausente; R10 y R11 seseleccionan independientemente entre H, alquilo C1-4 opcionalmente sustituido con uno a tres átomos de F y alcoxi C1-4 sustituido opcionalmente con uno a tres átomos de F; R1 es H, alquilo C1-4 opcionalmente sustituido con uno a tres átomos de F,arilo, -C(O)R14 en la que R14 es arilo, alquilo C1-4, aril-alquilo C1-4 heteroarilalquilo C1-4, en los que los restos alquilo de los grupos aril-alquilo C1-4 heteroalquilo C1-4 pueden estar sustituidos opcionalmente con uno a tres átomos de F, y endonde los restos arilo y heteroarilo de estos grupos pueden estar opcionalmente sustituidos con uno o más sustituyentes, preferiblemente por cero a dos sustituyentes, seleccionados independientemente entre halo, nitro, amino, ciano, alquilo C1-6opcionalmente sustituido con uno a tres átomos de F, y alcoxi C1-6 opcionalmente sustituido con uno a tres átomos de F; R2 y R3 se seleccionan independientemente entre H, alquilo C1-4, alcoxi C1-45, halo, arilo, aril-alquilo C1-4, heteroarilo yheteroaril-alquilo C1-4 en los que los restos alquilo de los grupos alquilo C1-4 y alcoxi C1-4 pueden estar sustituidos opcionalmente con uno a tres átomos de F y pueden estar también sustituidos en forma opcional con un sustituyente amino ohidroxi, y en los que los restos alquilo C1-4 los grupos aril-alquilo C1-4 y heteroaril-alquilo C1-4 pueden estar sustituidos de forma opcional con uno a tres átomos de F, y en los que los restos arilo y heteroarilo estos grupos pueden estarsustituidos de forma opcional con uno o más sustituyentes preferiblemente de cero a dos sustituyentes, seleccionados independientemente entre halo, nitro, amino, ciano, alquilo C1-6 sustituido opcionalmente con uno a tres átomos de F y alcoxi C1-6sustituido opcionalmente con uno a tres átomos de F; o uno de R2 y R3 pueden formar, junto con el C al cual están unidos, y junto con el C del anillo quinolina de W1, un anillo heterocíclico saturado o insaturado de 4 a 7 miembros de anillo , de loscuales 1 a 3 miembros de anillo pueden ser heteroátomos seleccionados entre N, O, y S y de los cuales los restantes miembros de anillo son C, con la condición de que cuando W1 forma un anillo con uno de R2 y R3, el otro de R2 y R3 está ausente, W1es CR5R6 y W2 es CR7R8, y la línea a trazos que se extiende desde W1 a W2 representa un doble enlace opcional, con la condición de que cuando haya un doble enlace entre W1 y W2, R5 y R7 están ausentes; R5, R6, R7 y R8 se seleccionanindependientemente entre H, halógeno, nitro, ciano, amino, alquilo (C1-4)-amino, dialquil(C1-4)-amino, alquilo (C1-4) opcionalmente sustituido con uno a tres átomos de flúor, y alcoxi C1-4 opcionalmente sustituido con uno a tres átomos de F; ocualquiera de dos entre R5, R6, R7 y R8 que estén unidos a átomos de C, tomados conjuntamente con el átomo o átomos de C a los cuales están unidos, forman un anillo carbocíclico C3-7 saturado o insaturado, con la condición de que el C del anillo dequinolinona de W1 no pueda formar un anillo con dos de R5, R6, R7 y R8 y forme también un anillo con R2 o R3; o una sal farmacéuticamente aceptable del mencionado compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41147502P | 2002-09-17 | 2002-09-17 | |
US41635502P | 2002-10-04 | 2002-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041260A1 true AR041260A1 (es) | 2005-05-11 |
Family
ID=32033549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103336A AR041260A1 (es) | 2002-09-17 | 2003-09-15 | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia |
Country Status (25)
Country | Link |
---|---|
US (1) | US20040138230A1 (es) |
EP (1) | EP1546143A1 (es) |
JP (1) | JP2006503106A (es) |
KR (1) | KR20050057404A (es) |
AP (1) | AP2005003250A0 (es) |
AR (1) | AR041260A1 (es) |
AU (1) | AU2003263413A1 (es) |
BR (1) | BR0314393A (es) |
CA (1) | CA2499326A1 (es) |
CO (1) | CO5550472A2 (es) |
EA (1) | EA200500342A1 (es) |
EC (1) | ECSP055676A (es) |
HR (1) | HRP20050248A2 (es) |
IS (1) | IS7710A (es) |
MA (1) | MA27438A1 (es) |
MX (1) | MXPA05002007A (es) |
NO (1) | NO20051826L (es) |
OA (1) | OA12923A (es) |
PA (1) | PA8582601A1 (es) |
PE (1) | PE20050132A1 (es) |
PL (1) | PL375981A1 (es) |
RS (1) | RS20050195A (es) |
TW (1) | TW200409771A (es) |
UY (1) | UY27976A1 (es) |
WO (1) | WO2004026864A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2505397A1 (en) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
CA2548447A1 (en) * | 2003-12-08 | 2005-06-23 | Warner-Lambert Company Llc | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
EP1701954A1 (en) * | 2003-12-31 | 2006-09-20 | Warner-Lambert Company LLC | N-substituted piperidine and piperazine derivatives |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
WO2008015516A1 (en) * | 2006-07-28 | 2008-02-07 | Pfizer Products Inc. | Fused tricyclic heterocycles for the treatment of schizophrenia |
TW200831498A (en) * | 2006-10-13 | 2008-08-01 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
NZ582124A (en) | 2007-05-21 | 2012-07-27 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
RU2010149311A (ru) | 2008-05-08 | 2012-06-20 | Аллерган, Инк. (Us) | ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ 1,7-ДИФЕНИЛ-1,2,3,5,6,7-ГЕКСАГИДРОПИРИДО [3,2,1-ij]ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ |
US20090281322A1 (en) * | 2008-05-08 | 2009-11-12 | Allergan, Inc. | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
US8653069B2 (en) * | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
WO2010031735A1 (en) * | 2008-09-22 | 2010-03-25 | F. Hoffmann-La Roche Ag | Piperazine d3 and 5-ht2a receptor modulators |
CA2736724A1 (en) * | 2008-09-23 | 2010-04-01 | F.Hoffmann-La Roche Ag | Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
CA2766033C (en) | 2009-06-25 | 2016-09-20 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
EP3309151A1 (en) * | 2009-06-25 | 2018-04-18 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
AU2014265021B2 (en) * | 2009-06-25 | 2016-07-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之pbk抑制劑 |
US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
RU2627469C2 (ru) | 2011-03-18 | 2017-08-08 | Алкермес Фарма Айэленд Лимитед | Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита |
US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
RU2601420C2 (ru) | 2011-07-28 | 2016-11-10 | Оцука Фармасьютикал Ко., Лтд. | СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА |
JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
CA2858787C (en) | 2011-12-15 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of tertiary amine compounds |
CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
WO2013142198A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
CA2943213C (en) | 2014-03-20 | 2022-07-05 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
JP5714152B2 (ja) * | 2014-03-26 | 2015-05-07 | 江蘇恒誼薬業有限公司 | アラルキルピペリジン(又はピペラジン)誘導体及びその統合失調症治療のための使用 |
CN106608875A (zh) * | 2015-10-26 | 2017-05-03 | 江苏恩华药业股份有限公司 | 一种稠和杂环类衍生物合成及其应用 |
CN106749219A (zh) | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
JPWO2020230802A1 (es) * | 2019-05-14 | 2020-11-19 | ||
CN114728956B (zh) * | 2019-11-18 | 2024-01-12 | 上海枢境生物科技有限公司 | 稠和杂环类衍生物及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3706427A1 (de) * | 1987-02-27 | 1988-09-08 | Boehringer Mannheim Gmbh | Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel |
GB8723763D0 (en) * | 1987-10-09 | 1987-11-11 | Hydro Tech Ltd | Liquid flow control device |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
JP2768981B2 (ja) * | 1989-06-22 | 1998-06-25 | シャープ株式会社 | 光メモリ素子 |
WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
US5143923B1 (en) * | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
TW300219B (es) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
DE19746612A1 (de) * | 1997-10-22 | 1999-04-29 | Basf Ag | 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
RS50340B (sr) * | 1999-06-23 | 2009-11-10 | Sanofi-Aventis Deutschland Gmbh., | Supstituisani benzimidazoli |
-
2003
- 2003-09-05 MX MXPA05002007A patent/MXPA05002007A/es unknown
- 2003-09-05 EA EA200500342A patent/EA200500342A1/ru unknown
- 2003-09-05 WO PCT/IB2003/003902 patent/WO2004026864A1/en not_active Application Discontinuation
- 2003-09-05 JP JP2004568902A patent/JP2006503106A/ja active Pending
- 2003-09-05 PL PL03375981A patent/PL375981A1/xx not_active Application Discontinuation
- 2003-09-05 CA CA002499326A patent/CA2499326A1/en not_active Abandoned
- 2003-09-05 EP EP03797433A patent/EP1546143A1/en not_active Withdrawn
- 2003-09-05 BR BR0314393-7A patent/BR0314393A/pt not_active IP Right Cessation
- 2003-09-05 AU AU2003263413A patent/AU2003263413A1/en not_active Abandoned
- 2003-09-05 RS YUP-2005/0195A patent/RS20050195A/sr unknown
- 2003-09-05 KR KR1020057004592A patent/KR20050057404A/ko active IP Right Grant
- 2003-09-05 OA OA1200500072A patent/OA12923A/en unknown
- 2003-09-05 AP AP2005003250A patent/AP2005003250A0/xx unknown
- 2003-09-12 US US10/660,908 patent/US20040138230A1/en not_active Abandoned
- 2003-09-12 PE PE2003000930A patent/PE20050132A1/es not_active Application Discontinuation
- 2003-09-15 UY UY27976A patent/UY27976A1/es not_active Application Discontinuation
- 2003-09-15 PA PA20038582601A patent/PA8582601A1/es unknown
- 2003-09-15 AR ARP030103336A patent/AR041260A1/es unknown
- 2003-09-16 TW TW092125508A patent/TW200409771A/zh unknown
-
2005
- 2005-02-24 IS IS7710A patent/IS7710A/is unknown
- 2005-03-15 EC EC2005005676A patent/ECSP055676A/es unknown
- 2005-03-16 HR HR20050248A patent/HRP20050248A2/hr not_active Application Discontinuation
- 2005-03-17 MA MA28152A patent/MA27438A1/fr unknown
- 2005-03-18 CO CO05025665A patent/CO5550472A2/es not_active Application Discontinuation
- 2005-04-15 NO NO20051826A patent/NO20051826L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0314393A (pt) | 2005-07-19 |
AU2003263413A1 (en) | 2004-04-08 |
US20040138230A1 (en) | 2004-07-15 |
EP1546143A1 (en) | 2005-06-29 |
PE20050132A1 (es) | 2005-03-21 |
WO2004026864A1 (en) | 2004-04-01 |
ECSP055676A (es) | 2005-07-06 |
PL375981A1 (en) | 2005-12-12 |
TW200409771A (en) | 2004-06-16 |
HRP20050248A2 (en) | 2005-10-31 |
EA200500342A1 (ru) | 2005-08-25 |
CA2499326A1 (en) | 2004-04-01 |
NO20051826L (no) | 2005-04-15 |
OA12923A (en) | 2006-10-13 |
MA27438A1 (fr) | 2005-07-01 |
CO5550472A2 (es) | 2005-08-31 |
PA8582601A1 (es) | 2004-05-26 |
IS7710A (is) | 2005-02-24 |
UY27976A1 (es) | 2004-04-30 |
MXPA05002007A (es) | 2005-04-28 |
KR20050057404A (ko) | 2005-06-16 |
AP2005003250A0 (en) | 2005-03-31 |
JP2006503106A (ja) | 2006-01-26 |
RS20050195A (en) | 2007-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR036875A1 (es) | Acidos hidroxamicos ciclicos como inhibidores de las metaloproteinasas de matriz y/o de la enzima de conversion del factor de necrosis de tumor alfa | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
AR041697A1 (es) | Piperazinil y diazepanil benzamidas y benzotiamidas; composiciones farmaceuticas que las contienen y su uso para la fabricacion de un medicamento | |
AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
AR017019A1 (es) | Compuestos derivados del 2-(4-aril o heteroarilpiperazin-1-ilmetil)-1h-indol, composiciones y su uso en la manufactura de medicamentos | |
AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
AR115464A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
PE20030705A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |